Patents Represented by Attorney, Agent or Law Firm Adrian G. Looney
-
Patent number: 6645982Abstract: The invention relates to crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1H-quinolin-2-one, 2,3-dihydroxy butanedioate salts having the formula shown below: and to pharmaceutical compositions containing the above compound, methods of treating hyperproliferative diseases, such as cancers, in mammals, especially humans by administering the above compound, and to methods of preparing the crystal forms of the above compound and related compounds.Type: GrantFiled: December 7, 2001Date of Patent: November 11, 2003Assignee: Pfizer IncInventors: Joseph P. Lyssikatos, Derek L. Tickner, Linda S. Newton, Zheng J. Li, Clifford N. Meltz
-
Patent number: 6645979Abstract: The invention described herein relates to a process for the preparation of (7-(3-carboxyphenyl)-4-chloroisoquinolin-1-yl)guanidine (I), intermediates thereto and new forms and formulations thereof, including the zwitterion monohydrate of (I), suitable for pharmaceutical use.Type: GrantFiled: October 29, 2001Date of Patent: November 11, 2003Assignee: Pfizer Inc.Inventors: Anne Bruckner, Michael Butters, Paul Vincent Fish, Michael Paul Fitzgerald, Julie Ann Macrae, Trevor Jack Newbury, Richard Anthony Storey
-
Patent number: 6579887Abstract: The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals.Type: GrantFiled: July 6, 2001Date of Patent: June 17, 2003Assignee: Pfizer IncInventors: Joseph P. Lyssikatos, Susan D. La Greca
-
Patent number: 6570017Abstract: The present invention relates to method for the preparation of dialkylpyridylboranes by reacting a pyridine Grignard reagent with an alkoxydialkylborane or a trialkylborane. The reaction can be conducted at a temperature ranging from about 0° C. to about 40° C. The pyridine Grignard reagent is preferably prepared in situ by the reaction of a Grignard reagent (RMgX) and a halopyridine in a suitable solvent, such as tetrahydrofuran, followed by the addition of an alkoxydialkylborane or a trialkylborane to form a dialkylpyridylborane.Type: GrantFiled: August 23, 2002Date of Patent: May 27, 2003Assignee: Pfizer IncInventor: David Harold Brown Ripin
-
Patent number: 6548526Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.Type: GrantFiled: March 9, 2001Date of Patent: April 15, 2003Assignee: Pfizer IncInventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
-
Patent number: 6541481Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.Type: GrantFiled: April 12, 2001Date of Patent: April 1, 2003Assignee: Pfizer IncInventors: John Charles Kath, Norma Jacqueline Tom, Zhengyu Liu, Eric David Cox, Joel Morris, Samit Kumar Bhattacharya
-
Patent number: 6495564Abstract: The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to a mammal requiring such treatment.Type: GrantFiled: August 26, 1999Date of Patent: December 17, 2002Assignee: Pfizer Inc.Inventors: Joseph P. Lyssikatos, Susan D. La Greca, Bingwei V. Yang
-
Patent number: 6492383Abstract: The invention relates to compounds of the formulas 1 and 2 and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.Type: GrantFiled: February 10, 2000Date of Patent: December 10, 2002Assignee: Pfizer Inc.Inventors: Michael John Munchhof, Susan Beth Sobolov-Jaynes, Matthew Arnold Marx
-
Patent number: 6465449Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.Type: GrantFiled: January 20, 2000Date of Patent: October 15, 2002Assignee: Pfizer Inc.Inventors: John Charles Kath, Norma Jacqueline Tom, Eric David Cox, Samit Kumar Bhattacharya
-
Patent number: 6452041Abstract: An efficient and selective process, capable of scale-up, to make itaconate derivatives of formula (IV), and/or succinate derivatives of formula (V) and/or (VI) by asymmetric hydrogenation of the itaconate derivatives. wherein R, R1 and R2 are as defined herein.Type: GrantFiled: October 15, 2001Date of Patent: September 17, 2002Assignee: Pfizer Inc.Inventors: Andrew Michael Derrick, Nicholas Murray Thomson
-
Patent number: 6388092Abstract: The present invention relates to compounds of formula 1 and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering compounds of formula 1 to the mammal. The invention also relates to intermediates and methods useful in synthesizing compounds of formula 1.Type: GrantFiled: April 17, 2001Date of Patent: May 14, 2002Assignee: Pfizer IncInventor: Bingwei V. Yang
-
Patent number: 6294552Abstract: The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to a mammal requiring such treatment.Type: GrantFiled: July 27, 2000Date of Patent: September 25, 2001Assignee: Pfizer Inc.Inventors: Joseph P. Lyssikatos, Susan D. La Greca
-
Patent number: 6294558Abstract: This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 orType: GrantFiled: December 15, 1999Date of Patent: September 25, 2001Assignee: Pfizer Inc.Inventors: Kazuo Ando, Tomoki Kato, Akiyoshi Kawai, Tomomi Nonomura
-
Patent number: 6284764Abstract: The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3 and R4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.Type: GrantFiled: January 20, 2000Date of Patent: September 4, 2001Assignee: Pfizer Inc.Inventors: John Charles Kath, Norma Jacqueline Tom, Zhengyu Liu, Eric David Cox, Joel Morris, Samit Kumar Bhattacharya
-
Patent number: 6258824Abstract: The present invention relates to compounds of formula 1 and pharmaceutically acceptable salts and solvates thereof wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering compounds of formula 1 to the mammal. The invention also relates to intermediates and methods useful in synthesizing compounds of formula 1.Type: GrantFiled: February 9, 2000Date of Patent: July 10, 2001Assignee: Pfizer Inc.Inventor: Bingwei V. Yang
-
Patent number: 6235764Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.Type: GrantFiled: May 21, 1999Date of Patent: May 22, 2001Assignee: Pfizer Inc.Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
-
Patent number: 6184380Abstract: A process for preparing a naphthyridone carboxylic acid and its derivatives makes use of side chain intermediates of formulae I and IV herein.Type: GrantFiled: January 25, 1999Date of Patent: February 6, 2001Assignee: Pfizer Inc.Inventors: Charles K. Chiu, Lewin T. Wint
-
Patent number: 6153609Abstract: A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.Type: GrantFiled: February 16, 1999Date of Patent: November 28, 2000Assignee: Pfizer IncInventors: Ralph P. Robinson, Todd A. Blumenkopf
-
Patent number: 6150377Abstract: The present invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, and R.sup.11 are as defined herein. The above compounds of formula 1 are useful in the treatment of hyperproliferative disorders, such as cancer, in mammals. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of inhibiting abnormal cell growth, including cancer, in a mammal by administering the compounds of formula 1 to a mammal requiring such treatment.Type: GrantFiled: August 26, 1999Date of Patent: November 21, 2000Assignee: Pfizer Inc.Inventors: Joseph P. Lyssikatos, Susan D. La Greca